ClinicalTrials.gg
CompletedNCT00541775Updated Aug 24, 2015Results posted

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

A Phase 3 interventional study of Sitagliptin and Comparator: Rosiglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
60th of 197
273 · median 102
Started
2006
with 12 others
Phase 3
74 of 198
none open now
Registered
34th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 60th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2006, is one of 74 in phase 3, and was the 34th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has Type 2 diabetes
  • Currently taking metformin >1500 mg/day for at least 10 weeks
  • Male or female

Exclusion criteria

Exclusion Criteria:

  • Patient has peripheral edema
  • History of type 1 diabetes
  • Patient required insulin within prior 8 weeks
  • Have participated or are currently participating in another study with an compound or device within 12 weeks of starting this study
  • Participating in a weight loss program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
273 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    sitagliptin 100 mg

    Drug: Sitagliptin · Drug: Comparator: Metformin

  • Active comparator
    Rosiglitazone

    rosiglitazone 8 mg

    Drug: Comparator: Rosiglitazone · Drug: Comparator: Metformin

  • Placebo comparator
    Placebo

    placebo

    Drug: Comparator: Placebo · Drug: Comparator: Metformin

Interventions

  • Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.

    Also known as: Januvia

  • DrugRosiglitazoneStudies of RosiglitazoneRosiglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.

    Also known as: Avandia

  • DrugComparator: Placebo

    placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1C (A1C) at Week 18

    A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent. The study hypothesis comparison was between sitagliptin versus placebo.

    Time frame: Baseline and 18 Weeks

Secondary outcomes

  1. Fasting Plasma Glucose (FPG) at Week 18

    The change from baseline is the Week 18 FPG minus the Week 0 FPG.

    Time frame: Baseline and 18 Weeks

  2. 2-hour Post-meal Glucose (PMG) at Week 18

    The change from baseline is the Week 18 PMG minus the Week 0 PMG.

    Time frame: Baseline and 18 Weeks

07

Results

Posted Jun 17, 2010

Participant flow

First Patient In: 16-June-2006. Last Patient Last Visit: 2-March-2007. 13 medical clinics in 3 countries in Europe and 23 in 4 countries in the rest of the world

Participant flow — Overall Study
MilestoneSitagliptinRosiglitazonePlacebo
Started948792
Completed858584
Not completed928
Withdrew: Adverse event321
Withdrew: Lack of efficacy003
Withdrew: Lost to follow-up002
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject and other502

Outcome measures

PrimaryHemoglobin A1C (A1C) at Week 18

A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent. The study hypothesis comparison was between sitagliptin versus placebo.

Time frame:
Baseline and 18 Weeks
Reported as:
Least squares mean · Percent of glycosylated hemoglobin (A1C)
Hemoglobin A1C (A1C) at Week 18
Percent of glycosylated hemoglobin (A1C)SitagliptinRosiglitazonePlacebo
Hemoglobin A1C (A1C) at Week 18-0.73 (-0.87 to -0.60)-0.79 (-0.92 to -0.65)-0.22 (-0.36 to -0.08)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <=0.001 · Mean difference (net): -0.51 · 95% CI -0.70 to -0.32Analysis of covariance with a term for treatment, and a covariate for baseline value.
SecondaryFasting Plasma Glucose (FPG) at Week 18

The change from baseline is the Week 18 FPG minus the Week 0 FPG.

Time frame:
Baseline and 18 Weeks
Reported as:
Least squares mean · mg/dL
Fasting Plasma Glucose (FPG) at Week 18
mg/dLSitagliptinRosiglitazonePlacebo
Fasting Plasma Glucose (FPG) at Week 18-11.7 (-18.6 to -4.9)-24.5 (-31.6 to -17.5)6.1 (-0.8 to 13.1)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <=0.001 · Mean difference (net): -17.8 · 95% CI -27.6 to -8.1Analysis of covariance with a term for treatment, and a covariate for baseline value.
Secondary2-hour Post-meal Glucose (PMG) at Week 18

The change from baseline is the Week 18 PMG minus the Week 0 PMG.

Time frame:
Baseline and 18 Weeks
Reported as:
Least squares mean · mg/dL
2-hour Post-meal Glucose (PMG) at Week 18
mg/dLSitagliptinRosiglitazonePlacebo
2-hour Post-meal Glucose (PMG) at Week 18-35.4 (-46.3 to -24.5)-51.3 (-62.5 to -40.1)-4.9 (-16.0 to 6.1)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <=0.001 · Mean difference (net): -30.5 · 95% CI -46.0 to -15.0Analysis of covariance with a term for treatment, and a covariate for baseline value.

Adverse events

Collected over Weeks 0 to 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—5/94 (5.3%)5/94 (5.3%)
Rosiglitazone—5/87 (5.7%)1/87 (1.1%)
Placebo—5/91 (5.5%)0/91 (0%)
Most frequent serious events
Most frequent serious events
EventSitagliptinRosiglitazonePlacebo
OverdoseInjury, poisoning and procedural complications2/943/872/91
Intentional overdoseInjury, poisoning and procedural complications0/941/870/91
SyncopeNervous system disorders0/941/870/91
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/940/871/91
Endometrial hyperplasiaReproductive system and breast disorders0/940/871/91
AsthmaRespiratory, thoracic and mediastinal disorders0/940/871/91
Angina unstableCardiac disorders1/940/870/91
Coronary artery diseaseCardiac disorders1/940/870/91
Skin lacerationInjury, poisoning and procedural complications1/940/870/91
Most frequent other events
Most frequent other events
EventSitagliptinRosiglitazonePlacebo
Blood glucose increasedInvestigations5/941/870/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinRosiglitazonePlaceboTotal
Mean55.2 ± 9.854.8 ± 10.555.3 ± 9.355.1 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinRosiglitazonePlaceboTotal
Female423238112
Male525554161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SitagliptinRosiglitazonePlaceboTotal
White575156164
Black0101
Asian363336105
Other1203
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)SitagliptinRosiglitazonePlaceboTotal
Mean157.5 ± 31.4156.9 ± 31.6160.0 ± 37.4158.1 ± 33.5
Hemoglobin A1C (A1C)
Hemoglobin A1C (A1C)(Percent of glycosylated hemoglobin (A1C))SitagliptinRosiglitazonePlaceboTotal
Mean7.8 ± 1.07.7 ± 0.87.7 ± 0.97.7 ± 0.9
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14. PubMed 18201203 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2007
First posted
Oct 10, 2007
Start
Jun 2006
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Results first posted
Jun 17, 2010
Last update
Aug 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00541775
Responsible party
Sponsor
First posted
Oct 10, 2007
Start date
Jun 2006
Primary completion
Mar 2007
Completion
Mar 2007
Results posted
Jun 17, 2010
Last update
Aug 24, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion